Follow Us on StockTwits

Analyst Actions and Breaking News

Posted by on March 20, 2017 7:19 AM
Categories: Business

Overnight Analyst Actions:


ILMN Outperform Leerink Partners

Initiates: None


MBLY Neutral Piper Jaffray/Simmons

Overnight Headlines By Ticker:

ABT Abbott Laboratories

3/19 15:47 Late-breaking data shows Abbott’s CardioMEMS HF system is effective in reducing heart failure hospitalizations and cost of care

3/18 12:52 Late-breaking data on Abbott’s MitraClip® System show continued benefit for people with Mitral Regurgitation

ACIA Acacia Communications, Inc

3/20 09:00 Will demonstrate BGA photonic integrated circuit improved RF interface, supports 1.2 Tbps coherent solution

ALQA Alliqua, Inc.

3/20 07:32 Announces the publication of a peer-reviewed Study Examining the Use of MIST Therapy for Deep Tissue Pressure Injuries

AMGN Amgen Inc

3/19 15:48 Presents analyses of PCSK9 inhibitor prescription rejection rates demonstrating significant access barriers for appropriate patients

3/18 13:12 Lowering LDL levels with Repatha (Evolocumab) did not adversely affect cognitive function in Phase 3 Study

AOBC American outdoor Brands (formerly Smith & Wesson)

3/17 16:56 Affirms Q4 adj EPS $0.32-0.42 v $0.37e, R$200-220M v $216Me – March investor presentation

ARTX Arotech Corp

3/20 08:20 Arotech Training and Simulation receives $9.5M U.S. Air Force IDIQ Award With Initial Task Orders Valued at $2.32M

DDD 3-D Systems Corp

3/20 09:02 Unveils Industry’s First Scalable, Fully-Integrated Additive Manufacturing Platform

GLD StreetTracks Gold Trust

3/18 22:31 SPDR Gold Trust ETF daily holdings fall 3.0 tonnes to 834.1 tonnes; 2nd straight decline

ILMN Illumina Inc

3/20 06:09 Leerink Partners Raised ILMN to Outperform from Market Perform, price target: $195

JAZZ Jazz Pharmaceuticals

3/20 09:00 Announces positive results from Phase 3 TONES 3 and TONES 4 studies of JZP-110 in patients with Obstructive Sleep Apnea

MBLY Mobileye NV

3/19 21:56 May seek higher offers from other companies – NY Post citing analyst

3/19 18:48 Piper Jaffray/Simmons Cuts MBLY to Neutral from Overweight, price target: $63.54

NKTR Nektar Therapeutics

3/20 07:30 NKTR-181 meets Primary and Secondary Endpoints in Phase 3 SUMMIT-07 Study in Chronic Pain

3/20 07:25 Halted: News pending

NVS Novartis AG

3/18 12:45 New analysis shows Novartis Entresto improves glycemic control in reduced ejection fraction heart failure patients with diabetes

OCLR Oclaro, Inc

3/20 07:09 Selected by Ciena to develop 400G Coherent Transponders

OPK Opko Health Inc

3/19 15:40 FDA grants orphan drug designation to Opko drug for treatment of Dravet Syndrome